These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27141340)

  • 1. The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers.
    Bertucci F; Finetti P; Birnbaum D; Mamessier E
    Oncoimmunology; 2016 Mar; 5(3):e1085148. PubMed ID: 27141340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive value of PDL1 expression in breast cancer.
    Sabatier R; Finetti P; Mamessier E; Adelaide J; Chaffanet M; Ali HR; Viens P; Caldas C; Birnbaum D; Bertucci F
    Oncotarget; 2015 Mar; 6(7):5449-64. PubMed ID: 25669979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.
    Ren X; Wu H; Lu J; Zhang Y; Luo Y; Xu Q; Shen S; Liang Z
    Cancer Biol Ther; 2018 May; 19(5):373-380. PubMed ID: 29336717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.
    Bertucci F; Finetti P; Colpaert C; Mamessier E; Parizel M; Dirix L; Viens P; Birnbaum D; van Laere S
    Oncotarget; 2015 May; 6(15):13506-19. PubMed ID: 25940795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer.
    Polónia A; Pinto R; Cameselle-Teijeiro JF; Schmitt FC; Paredes J
    J Clin Pathol; 2017 Oct; 70(10):860-867. PubMed ID: 28373294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
    Beckers RK; Selinger CI; Vilain R; Madore J; Wilmott JS; Harvey K; Holliday A; Cooper CL; Robbins E; Gillett D; Kennedy CW; Gluch L; Carmalt H; Mak C; Warrier S; Gee HE; Chan C; McLean A; Walker E; McNeil CM; Beith JM; Swarbrick A; Scolyer RA; O'Toole SA
    Histopathology; 2016 Jul; 69(1):25-34. PubMed ID: 26588661
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Billon E; Finetti P; Bertucci A; Niccoli P; Birnbaum D; Mamessier E; Bertucci F
    Oncoimmunology; 2019; 8(11):e1655362. PubMed ID: 31646101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
    Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
    Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas.
    Tabanelli V; Corsini C; Fiori S; Agostinelli C; Calleri A; Orecchioni S; Melle F; Motta G; Rotili A; Di Napoli A; Pileri SA
    Hum Pathol; 2019 Aug; 90():60-69. PubMed ID: 31125630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of PDL1 expression in pancreatic cancer.
    Birnbaum DJ; Finetti P; Lopresti A; Gilabert M; Poizat F; Turrini O; Raoul JL; Delpero JR; Moutardier V; Birnbaum D; Mamessier E; Bertucci F
    Oncotarget; 2016 Nov; 7(44):71198-71210. PubMed ID: 27589570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling.
    Lucas J; Hsieh TC; Halicka HD; Darzynkiewicz Z; Wu JM
    Int J Oncol; 2018 Oct; 53(4):1469-1480. PubMed ID: 30066852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed cell death 1 and programmed cell death ligand 1 expression in invasive breast carcinoma using CAL10 and NAT105 immunostaining.
    Durak Ö; Bozkurt KK; Çiriş İM; Kocer M; Eroğlu HE
    Biotech Histochem; 2023 Feb; 98(2):147-154. PubMed ID: 36281760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDL1 expression is an independent prognostic factor in localized GIST.
    Bertucci F; Finetti P; Mamessier E; Pantaleo MA; Astolfi A; Ostrowski J; Birnbaum D
    Oncoimmunology; 2015 May; 4(5):e1002729. PubMed ID: 26155391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status.
    Ott E; Bilonda L; Dansette D; Deleine C; Duchalais E; Podevin J; Volteau C; Bennouna J; Touchefeu Y; Fourquier P; El Alami Thomas W; Chetritt J; Bezieau S; Denis M; Toquet C; Mosnier JF; Jarry A; Bossard C
    Oncoimmunology; 2019; 8(4):e1562834. PubMed ID: 30906656
    [No Abstract]   [Full Text] [Related]  

  • 17. CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression.
    Boudin L; De Nonneville A; Finetti P; Guittard G; Nunes JA; Birnbaum D; Mamessier E; Bertucci F
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
    Wang X; Liu Y
    Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Significance of
    Uhercik M; Sanders AJ; Owen S; Davies EL; Sharma AK; Jiang WG; Mokbel K
    Anticancer Res; 2017 Aug; 37(8):4249-4254. PubMed ID: 28739716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.
    Bertucci F; Finetti P; Perrot D; Leroux A; Collin F; Le Cesne A; Coindre JM; Blay JY; Birnbaum D; Mamessier E
    Oncoimmunology; 2017; 6(3):e1278100. PubMed ID: 28405501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.